| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:1675421 | IVR | 63 mg/L | 63 mg/L | Affects catecholamine biosynthesis | Metabolic endocrine-mediated perturbations;Neurological endocrine-mediated perturbations |
| IVR | 250 mg/L | 250 mg/L | Affects catecholamine biosynthesis | Metabolic endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 125 mg/L | 125 mg/L | Affects catecholamine biosynthesis | Metabolic endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 31 mg/L | - | No significant effects observed | - | |
| PMID:2447477 | IVR | 31 mg/L | 31 mg/L | Decreased levels of norepinephrine | Neurological endocrine-mediated perturbations |
| IVR | 63 mg/L | 63 mg/L | Affects dopaminergic pathways | Neurological endocrine-mediated perturbations | |
| IVR | 63 mg/L | 63 mg/L | Affects social behavior | Neurological endocrine-mediated perturbations | |
| IVR | 250 mg/L | 250 mg/L | Affects dopaminergic pathways | Neurological endocrine-mediated perturbations | |
| IVR | 250 mg/L | 250 mg/L | Decreased dopamine levels | Neurological endocrine-mediated perturbations | |
| IVR | 250 mg/L | 250 mg/L | Decreased levels of norepinephrine | Neurological endocrine-mediated perturbations | |
| IVR | 100 mg/L | 100 mg/L | Decreased dopamine levels | Neurological endocrine-mediated perturbations | |
| IVR | 100 mg/L | 100 mg/L | Affects dopaminergic pathways | Neurological endocrine-mediated perturbations | |
| IVR | 100 mg/L | 100 mg/L | Decreased levels of norepinephrine | Neurological endocrine-mediated perturbations | |
| IVR | 125 mg/L | 125 mg/L | Decreased dopamine levels | Neurological endocrine-mediated perturbations | |
| PMID:3229585 | IVR | 160 mg/L | 160 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations |
| IVR | 160 mg/L | 160 mg/L | Neuronal degeneration | Neurological endocrine-mediated perturbations | |
| IVR | 160 mg/L | 160 mg/L | Atrophy of adrenal gland | Metabolic endocrine-mediated perturbations | |
| IVR | 160 mg/L | 160 mg/L | Decreased thymus gland weights | Immunological endocrine-mediated perturbations | |
| IVR | 160 mg/L | 160 mg/L | Changes in testicular morphology | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.